Actualités et vidéos - MALLINCKRODT PLC

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting PR Newswire DUBLIN, Oct. 24, 2022 – Five scientific abstracts spanning clinical and health economic outcomes research will be presented at the ACG Scientific Meeting, showcasing the breadth of Mallinckrodt's commitment to HRS patients with rapid reduction in kidney function 1 – DUBLIN , Oct. 24,...

Mallinckrodt Receives Approval to List on NYSE American PR Newswire DUBLIN, Oct. 24, 2022 Trading on NYSE American Expected to Commence Under Ticker Symbol "MNK" on October 27, 2022 DUBLIN , Oct. 24, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, today announced that it has received approval to list its ordinary shares on NYSE American. Trading of the Company's ordinary shares on NYSE American is expected to...

Mallinckrodt to Report Earnings Results for Third Quarter 2022 PR Newswire DUBLIN, Oct. 18, 2022 DUBLIN , Oct. 18, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF ), a global specialty pharmaceutical company, today announced that it will report third quarter 2022 earnings results for the period ended Sept. 30, 2022 , on Tuesday, Nov. 8 , 2022. A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows: Live Call Participant Registration (including...

Mallinckrodt Announces Appointment of Susan Silbermann to its Board of Directors PR Newswire DUBLIN, Oct. 6, 2022 DUBLIN , Oct. 6, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, today announced that it has appointed Susan Silbermann to its Board of Directors, effective October 5, 2022 . With the addition of Ms. Silbermann, the Mallinckrodt Board will expand to nine directors, eight of whom are independent....

Mallinckrodt Announces Submission of 510(k) to the U.S. FDA for Inhaled Nitric Oxide Delivery System PR Newswire DUBLIN, Sept. 28, 2022 — If 510(k) cleared, this next-generation investigational inhaled nitric oxide delivery system would be the latest in a long line of dual channel delivery systems building on Company's dedication to meeting clinicians' evolving needs — DUBLIN , Sept. 28, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, today...

Mallinckrodt Announces Appointment of Lisa French as Chief Commercial Officer PR Newswire DUBLIN, Sept. 19, 2022 DUBLIN , Sept. 19, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, today announced it has appointed Lisa French as Executive Vice President and Chief Commercial Officer, effective October 1, 2022 . Ms. French brings more than 30 years of commercial biopharmaceutical experience and will oversee the...

Mallinckrodt Receives U.S. FDA Approval for Terlivaz® (terlipressin) for injection for the Treatment of Hepatorenal Syndrome (HRS) PR Newswire DUBLIN, Sept. 14, 2022 – Terlivaz is the first and only FDA-approved treatment for adults with HRS involving rapid reduction in kidney function 1 – DUBLIN , Sept. 14, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Terlivaz ®...

Mallinckrodt plc Provides Update on Executive Committee PR Newswire DUBLIN, Aug. 17, 2022 DUBLIN , Aug. 17, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, today provided an update on its Executive Committee. Reflective of Mallinckrodt's efforts to build on recent progress, stabilize the business and create a stronger company for the long term, the following leaders will serve on the Executive Committee and...

Mallinckrodt Announces Appointment of Karen Ling to Its Board of Directors PR Newswire DUBLIN, Aug. 17, 2022 DUBLIN , Aug. 17, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, today announced that Karen Ling has been appointed to the Company's Board of Directors, effective August 12, 2022 . With the addition of Ms. Ling, the Mallinckrodt Board will expand to eight directors, seven of whom are independent. "We...

Mallinckrodt plc Reports Second Quarter 2022 Financial Results and Provides 2022 Financial Guidance PR Newswire DUBLIN, Aug. 11, 2022 Focused on Advancing Branded Pipeline with Anticipated Launches and Bringing Existing Products to New Markets and Geographies Committed to Strengthening Balance Sheet, with a Disciplined Capital Allocation Focus; Benefiting from Cash Generation and Significant Liquidity Appointed New President & CEO and New Board of Directors with Deep Expertise and Decades of...

MALLINCKRODT TO REPORT EARNINGS RESULTS FOR SECOND QUARTER 2022 AND PROVIDE BUSINESS UPDATE PR Newswire DUBLIN, Aug. 3, 2022 DUBLIN , Aug. 3, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, announced today that it will report second quarter 2022 earnings results for the period ended July 1, 2022, on Thursday, August. 11, 2022. A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows: Directly via the...

Mallinckrodt to Present Data on Terlipressin in Adult Patients with Hepatorenal Syndrome (HRS) at the European Association for the Study of the Liver (EASL) 2022 International Liver Congress PR Newswire DUBLIN, June 23, 2022 -Post-hoc analyses showcase Mallinckrodt's commitment to patients with HRS involving rapid reduction in kidney function, 1 an acute and life-threatening condition 2 - DUBLIN , June 23, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global biopharmaceutical...

Mallinckrodt Emerges from Chapter 11 with Strengthened Balance Sheet and Enhanced Financial Flexibility PR Newswire DUBLIN, Ireland, June 16, 2022 Appoints Sigurdur Olafsson as President and Chief Executive Officer DUBLIN, Ireland , June 16, 2022 /PRNewswire/ -- Mallinckrodt plc (" Mallinckrodt " or the "Company") today announced that it has successfully completed its reorganization process, emerged from Chapter 11 and completed the Irish Examinership proceedings. The Company is moving forward...

Mallinckrodt Announces Resubmission of Terlipressin to the FDA for the Treatment of Hepatorenal Syndrome PR Newswire DUBLIN, June 13, 2022 DUBLIN , June 13, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced the resubmission of the Company's New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational agent terlipressin to treat adults with hepatorenal syndrome (HRS) involving rapid reduction in kidney...

Mallinckrodt Announces Anticipated Chapter 11 Emergence and Provides Update on Trading of New Ordinary Shares PR Newswire DUBLIN, June 13, 2022 DUBLIN , June 13, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) (" Mallinckrodt " or the "Company") today announced that it expects to complete its reorganization process, emerge from Chapter 11 and complete the Irish Examinership proceedings in the coming days. On the effective date of emergence, all of Mallinckrodt's existing ordinary shares...

New Retrospective Data on African Americans with Advanced Symptomatic Sarcoidosis Treated with Acthar® Gel (Repository Corticotropin Injection) Presented at the American Thoracic Society Annual International Conference PR Newswire DUBLIN, May 17, 2022 Retrospective medical chart review subgroup analysis showed Acthar Gel was associated with overall symptom improvement and reduction in use of concomitant medications in African Americans DUBLIN , May 17, 2022 /PRNewswire/ -- Mallinckrodt plc ,...

High Court of Ireland Confirms Mallinckrodt Scheme of Arrangement PR Newswire DUBLIN, April 27, 2022 Company Expects to Complete Irish Examinership and Emerge from Chapter 11 in the Next Few Weeks DUBLIN , April 27, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) (" Mallinckrodt " or the "Company") today announced that the High Court of Ireland (the "Irish High Court") has made an Order confirming the scheme of arrangement between the Company, its creditors and members (the "Scheme") as...

Mallinckrodt Announces Publication of Real-World Data from Retrospective Study on the Investigational Use of Inhaled Nitric Oxide in Hospitalized COVID-19 Patients PR Newswire DUBLIN, April 13, 2022 – Medical chart review study, published in Drugs in Context , evaluated the real-world use of INOmax ® (nitric oxide) gas, for inhalation in hospitalized COVID-19 patients with mild-to-moderate acute respiratory distress syndrome (ARDS) in the U.S. – DUBLIN , April 13, 2022 /PRNewswire/ --...

Retrospective Study on Real-World Treatment Patterns and Outcomes of Acthar® Gel (Repository Corticotropin Injection) in Patients with Refractory Rheumatoid Arthritis Published in Drugs in Context PR Newswire DUBLIN, March 28, 2022 – Electronic medical chart analysis showed Acthar Gel was associated with clinical improvements and a reduction in prescriptions for concomitant medications in refractory rheumatoid arthritis patients – DUBLIN , March 28, 2022 /PRNewswire/ -- Mallinckrodt plc ,...

Mallinckrodt Provides a Regulatory Update on Terlipressin PR Newswire DUBLIN, Feb. 22, 2022 DUBLIN , Feb. 22, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Company's New Drug Application (NDA) seeking approval for the investigational agent terlipressin to treat adults with hepatorenal syndrome (HRS), an acute and life-threatening...